Clinical trial · Interventional
AZD1152 in Patients With Advanced Solid Malignancies-Study 1
A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2 Hour Intravenous Infusion on Two Dose Schedules in Patients With Advanced Solid Malignancies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Efficacy seen in the solid tumour patient population was not sufficient to continue research with AZD1152 monotherapy in solid tumors at that time.
Summary
Brief summary (as posted)
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 2-hour infusion every week and every 2 weeks in patients with advanced solid malignancies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AZD1152 | Drug | Barasertib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Safety and Tolerability
- timeFrame
- Assessed at each visit
Secondary outcomes (3)
- measure
- Pharmacokinetics
- timeFrame
- Assessed at predetermined timepoints after dose administration
- measure
- Effect on biomarkers
- timeFrame
- Assessed after treatment
- measure
- Anti-tumor activity
- timeFrame
- Assessed after treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological or cytological confirmation of a solid, malignant tumour * At least measurable or non measurable site of disease as defined by modified RECIST criteria. Exclusion Criteria: * Participation in an investigational drug study within 30 days prior to entry or who have not recovered from the effects of an investigational study drug * Treatment with radiotherapy/chemotherapy with 4 weeks of first dose * Recent major surgery within 4 weeks prior to entry to the study
References
Publications (0)
Data not yet available